Microlife WatchBP O3 (BP 3MZ1-1)
The technology used in the Microlife WatchBP O3 (BP 3MZ1-1), to measure blood pressure, is among the best rated for accuracy by Medaval Ltd. It has passed in two clinical validation studies, between general and specific populations, according to recognised standard protocols, as published in peer-reviewed publications.
Accuracy Assessment | Recommendation | Basis | ||
---|---|---|---|---|
Medaval | ★★★ Recommendation | Recent clinical validation; recent protocol; multiple clinical validations | ||
BIHS | ABPM | Published evidence | ||
ESH | ABPM | Published evidence |
Ragazzo F, Saladini F, Palatini P. Validation of the Microlife WatchBP O3 device for clinic, home, and ambulatory blood pressure measurement, according to the International Protocol. Blood Press Monit. 2010 Feb;15(1):59-62. doi: 10.1097/MBP.0b013e32833531ca. PMID: 20075717.
ESH-IP:2002 - Pass General population
Stergiou GS, Tzamouranis D, Nasothimiou EG, Karpettas N, Protogerou A. Are there really differences between home and daytime ambulatory blood pressure? Comparison using a novel dual-mode ambulatory and home monitor. J Hum Hypertens. 2010 Mar;24(3):207-12. Epub: 2009 Jul 16. doi: 10.1038/jhh.2009.60. PMID: 19609285.
ESH-IP:2002 - Pass General population
Azaki A, Diab R, Harb A, Asmar R, Chahine MN. Questionable accuracy of home blood pressure measurements in the obese population - Validation of the Microlife WatchBP O3® and Omron RS6® devices according to the European Society of Hypertension-International Protocol. Vasc Health Risk Manag. 2017;13:61-9. Epub: 2017 Feb 27. doi: 10.2147/VHRM.S126285. PMID: 28280348. Available from: PMC5338962. eCollection 2017.
ESH-IP:2010 - Fail Obese subjects (BMI ≥ 30 kg/m²)